Clinical Trials
Page 3 • 12 itemsAccess global clinical trial data, regulatory updates, and competitive intelligence for strategic pharma R&D and investment decisions.
Novel Immunotherapies Advanced Melanoma: EMA Approval & Phase 3 Insights
Discover the groundbreaking EMA-approved immunotherapies for advanced melanoma and insights from recent Phase 3 trials shaping future treatments.
European Biomarker-Driven Trials: EMA Regulatory Framework & Success Rates
This article delves into the EMA's regulatory framework for biomarker-driven trials, highlighting success rates and implications for drugs like Keytruda in treating melanoma.
EU Clinical Trial Site Selection: Impact of New Qualification Requirements on Timelines
This article examines the implications of new qualification requirements on the timelines for clinical trial site selection in the EU, particularly for oncology drugs.
EU Clinical Trial Ethics Committees: Analysis of Decision Patterns & Timelines
This article analyzes the decision-making patterns and timelines of EU Clinical Trial Ethics Committees, focusing on their impact on drug development in oncology.
Boehringer Ingelheim's Survodutide Achieves 16.6% Weight Loss in Phase 2 Obesity Trial, Outperforming Current Market Leaders
Survodutide delivered 39.2 lb average weight loss in 76-week trial, potentially superior to Wegovy and Zepbound in competitive obesity market.
Silexion Therapeutics Submits Phase 2/3 Trial Application for SIL204 KRAS-Targeted Pancreatic Cancer Treatment
Silexion Therapeutics successfully submits Phase 2/3 clinical trial application to Germany's BfArM for SIL204, targeting KRAS-driven pancreatic cancer.
Novo Nordisk Presents New Wegovy Data for Women with Obesity at European Congress on Obesity 2026
Novo Nordisk unveils new clinical data on Wegovy for women with obesity and next-generation weight loss treatments at European Congress on Obesity in Istanbul.
Cytokinetics MYQORZO (Aficamten) Takes Center Stage at European Society of Cardiology Heart Failure 2026 Congress
Cytokinetics presents nine studies on MYQORZO (aficamten) at ESC Heart Failure 2026, including late-breaking science on the newly approved oHCM treatment.
Artiva Biotherapeutics' AlloNK Receives FDA Fast Track Designation for Refractory Rheumatoid Arthritis Treatment
FDA grants Fast Track Designation to Artiva's AlloNK (AB-101) for refractory rheumatoid arthritis, accelerating development of innovative NK cell therapy.
Opella's Essentiale Shows 2.5x Greater Liver Fat Reduction in Breakthrough EXCEL Trial for Fatty Liver Disease
Opella's Essentiale essential phospholipids demonstrated 2.5 times greater liver fat reduction vs diet/exercise alone in MASLD patients in EXCEL trial.
Mundipharma's REZZAYO (Rezafungin) Meets Primary Endpoint in Phase III ReSPECT Trial for Fungal Disease Prevention
Mundipharma announces positive Phase III ReSPECT trial results for REZZAYO (rezafungin) in preventing invasive fungal diseases in stem cell transplant patients.
Brii Bio's Elebsiran Shows Durable Hepatitis B Control in APASL 2026 Cross-Study Analysis
Brii Bio's elebsiran combined with pegylated interferon demonstrates sustained HBsAg loss and favorable off-treatment outcomes in hepatitis B patients.